Table 6.
Blood tests investigating factors potentially associated with paresthesias among cases, clinic controls, and community controls
| Cases | Clinic Controls | Community Controls | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood measure | N | Median | Min | Max | N | Median | Min | Max | N | Median | Min | Max | p- value* |
p- value** |
| Vitamin B12 (pg/mL) | 41 | 546 | 230 | 2500 | 38 | 439 | 222 | 2500 | 19 | 493 | 209 | 1150 | 0.8 | 0.5 |
| Methylmalonic acid (umol/L) | 40 | 0.145 | 0.05 | 0.33 | 38 | 0.15 | 0.05 | 0.29 | 20 | 0.155 | 0.11 | 0.47 | 0.4 | 0.4 |
| Folate (ng/mL) | 40 | 12.8 | 4.6 | 60 | 38 | 12.1 | 5 | 60 | 19 | 13.5 | 9.2 | 60 | 0.2 | 0.8 |
| Hemoglobin A1c (%) | 41 | 5.4 | 4.8 | 6.7 | 38 | 5.45 | 4.3 | 6.4 | 18 | 5.35 | 5 | 9.4 | 0.7 | 0.9 |
| Glucose, fasting (mg/dL) | 40 | 86.5 | 70 | 107 | 38 | 85 | 64 | 111 | 18 | 83 | 59 | 196 | 0.5 | 0.4 |
| ANA (inverse titers) | 32 | 20 | 20 | 1280 | 25 | 20 | 20 | 640 | 15 | 20 | 20 | 160 | 0.5 | 0.2 |
| C-reactive protein (mg/L) | 41 | 2.3 | 0.1 | 11 | 38 | 2.05 | 0.1 | 10 | 19 | 1.8 | 0.4 | 9.8 | 0.6 | 1 |
| Gliadin peptide antibody IgA (units) | 39 | 5 | 2 | 37 | 36 | 5 | 2 | 15 | 20 | 5 | 3 | 15 | 0.4 | 0.3 |
| Gliadin peptide antibody IgG (units) | 39 | 3 | 2 | 28 | 36 | 2 | 2 | 16 | 20 | 3 | 1 | 5 | 0.4 | 0.2 |
| Lead concentration (μg/dL) | 39 | 1 | 1 | 2.9 | 37 | 1 | 1 | 2.4 | 18 | 1 | 1 | 3 | 0.4 | 0.2 |
| Lyme antibody IgG/IgM (Western blot [normal < 0.91]) | 40 | 0.32 | 0.11 | 1 | 37 | 0.34 | 0.08 | 1.1 | 20 | 0.31 | 0.11 | 2.14 | 0.9 | 0.8 |
*
p from the Kruskall-Wallis tests comparing cases, clinic controls and community controls
**
p from the Wilcoxon rank-sum test comparing cases and clinic controls
¶
Lead levels shown by the laboratory as < 2.0 were assigned a value of 1.0.